Transdermal Patch + Loxoprofen sodium + Placebo (for loxoprofen sodium) + Placebo (for transdermal patch)

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Trauma

Conditions

Trauma, Pain

Trial Timeline

Oct 1, 2015 → Dec 1, 2016

NCT ID

NCT02616068

About Transdermal Patch + Loxoprofen sodium + Placebo (for loxoprofen sodium) + Placebo (for transdermal patch)

Transdermal Patch + Loxoprofen sodium + Placebo (for loxoprofen sodium) + Placebo (for transdermal patch) is a phase 3 stage product being developed by Daiichi Sankyo for Trauma. The current trial status is completed. This product is registered under clinical trial identifier NCT02616068. Target conditions include Trauma, Pain.

What happened to similar drugs?

8 of 17 similar drugs in Trauma were approved

Approved (8) Terminated (5) Active (5)

✅Galcanezumab-GnlmEli LillyApproved

✅Placebo + sertralineJohnson & JohnsonApproved

✅Adjunctive asenapineMerckApproved

✅AlendronateMerckApproved

✅RivastigmineNovartisApproved

✅ZiprasidonePfizerApproved

✅AbobotulinumtoxinA + Normal salineIpsenApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02616068	Phase 3	Completed	Oct 1, 2015	Dec 1, 2016	Trauma

Competing Products

20 competing products in Trauma

See all competitors

Product	Company	Stage	Hype Score
Duloxetine + Sugar pill	Eli Lilly	Phase 2	27
Neurosteroid enantiomer	Oragenics	Phase 2	32
Celecoxib	Astellas Pharma	Pre-clinical	26
Mupirocin Calcium Cream, 2% + Bactroban® Cream + Cream vehicle of test product	Sun Pharmaceutical	Phase 1	29
Duloxetine hydrochloride	Eli Lilly	Phase 3	36
Galcanezumab-Gnlm	Eli Lilly	Approved	43
SYN117 (nepicastat) + Placebo comparator	Johnson & Johnson	Phase 2	27
Nepicastat + Placebo	Johnson & Johnson	Phase 2	35
JNJ-17299425	Johnson & Johnson	Phase 2	27
Placebo + sertraline	Johnson & Johnson	Approved	35
Quetiapine Fumarate + quetiapine fumarate placebo	AstraZeneca	Phase 3	40
Adjunctive asenapine	Merck	Approved	43
Rizatriptan + Placebo	Merck	Pre-clinical	18
Alendronate	Merck	Approved	39
Iloperidone + Placebo	Novartis	Phase 2	27
AMG 334	Novartis	Phase 2	35
Rivastigmine	Novartis	Phase 3	40
Rivastigmine	Novartis	Approved	43
Balovaptan + Placebo	Roche	Phase 2	35
Erenumab	Amgen	Phase 2	35